Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb

Eloisa Velasco,1 Mª Victoria Ribera,2 Joan Pi3 1Department of Orthopedic Surgery, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain; 2Department of Anesthesiology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Department of Orthopedics and T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Velasco E, Ribera MV, Pi J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Durolane Hyaluronic acid Osteoarthritis Pain Rhizarthrosis Viscosupplementation Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/1940463a5efd46819f8a718898548f4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1940463a5efd46819f8a718898548f4a
record_format	dspace
spelling	oai:doaj.org-article:1940463a5efd46819f8a718898548f4a2021-12-02T06:09:20ZSingle-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb1179-156Xhttps://doaj.org/article/1940463a5efd46819f8a718898548f4a2017-03-01T00:00:00Zhttps://www.dovepress.com/single-arm-open-label-study-of-durolane-nasha-nonanimal-hyaluronic-aci-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XEloisa Velasco,1 Mª Victoria Ribera,2 Joan Pi3 1Department of Orthopedic Surgery, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain; 2Department of Anesthesiology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Department of Orthopedics and Traumatology, Parc Taulí University Hospital, Sabadell, Barcelona, Spain Introduction: Osteoarthritis of the trapeziometacarpal (TMC) joint of the thumb – also known as rhizarthrosis – is painful and has a significant impact on quality of life. Intra-articular injection of hyaluronic acid may potentially meet the need for effective, minimally invasive intervention in patients not responding adequately to initial treatment. We aimed to confirm the safety and effectiveness of viscosupplementation with Durolane (NASHA nonanimal hyaluronic acid) in rhizarthrosis.Patients and methods: This was a prospective, single-arm, multicenter, open-label study with a 6-month follow-up period. Eligible patients had Eaton–Littler grade II–III rhizarthrosis in one TMC joint with pain and visual analog scale (VAS) pain score ≥4 (scale: 0–10). A single injection of NASHA was administered to the affected TMC joint. The primary effectiveness variable was change from baseline in VAS pain score.Results: Thirty-five patients (mean age 60.8 years; 85.7% female) received NASHA and completed the study. The least-squares mean change from baseline in VAS pain score over 6 months was –2.00, a reduction of 27.8% (p<0.001). The reduction in pain exceeded 25% as early as month 1 (26.5%), and gradual improvement was observed throughout the 6-month follow-up period. Secondary effectiveness parameters included QuickDASH (shortened version of Disabilities of the Arm, Shoulder, and Hand [DASH]), Kapandji thumb opposition test, radial abduction, metacarpophalangeal (MCP) joint flexion, and pinch (clamp) strength. Most of these measurements showed statistically significant improvements from baseline over 6 months. Five adverse events (injection site reactions) were reported in four patients (11.4%), and there were no serious or allergic reactions.Conclusion: This study suggests that viscosupplementation using NASHA is effective and well tolerated in treating the symptoms of rhizarthrosis. Keywords: Durolane, hyaluronic acid, osteoarthritis, pain, rhizarthrosis, viscosupplementationVelasco ERibera MVPi JDove Medical PressarticleDurolaneHyaluronic acidOsteoarthritisPainRhizarthrosisViscosupplementationDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 9, Pp 61-66 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Durolane Hyaluronic acid Osteoarthritis Pain Rhizarthrosis Viscosupplementation Diseases of the musculoskeletal system RC925-935
spellingShingle	Durolane Hyaluronic acid Osteoarthritis Pain Rhizarthrosis Viscosupplementation Diseases of the musculoskeletal system RC925-935 Velasco E Ribera MV Pi J Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
description	Eloisa Velasco,1 Mª Victoria Ribera,2 Joan Pi3 1Department of Orthopedic Surgery, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain; 2Department of Anesthesiology, Vall d’Hebron University Hospital, Barcelona, Spain; 3Department of Orthopedics and Traumatology, Parc Taulí University Hospital, Sabadell, Barcelona, Spain Introduction: Osteoarthritis of the trapeziometacarpal (TMC) joint of the thumb – also known as rhizarthrosis – is painful and has a significant impact on quality of life. Intra-articular injection of hyaluronic acid may potentially meet the need for effective, minimally invasive intervention in patients not responding adequately to initial treatment. We aimed to confirm the safety and effectiveness of viscosupplementation with Durolane (NASHA nonanimal hyaluronic acid) in rhizarthrosis.Patients and methods: This was a prospective, single-arm, multicenter, open-label study with a 6-month follow-up period. Eligible patients had Eaton–Littler grade II–III rhizarthrosis in one TMC joint with pain and visual analog scale (VAS) pain score ≥4 (scale: 0–10). A single injection of NASHA was administered to the affected TMC joint. The primary effectiveness variable was change from baseline in VAS pain score.Results: Thirty-five patients (mean age 60.8 years; 85.7% female) received NASHA and completed the study. The least-squares mean change from baseline in VAS pain score over 6 months was –2.00, a reduction of 27.8% (p<0.001). The reduction in pain exceeded 25% as early as month 1 (26.5%), and gradual improvement was observed throughout the 6-month follow-up period. Secondary effectiveness parameters included QuickDASH (shortened version of Disabilities of the Arm, Shoulder, and Hand [DASH]), Kapandji thumb opposition test, radial abduction, metacarpophalangeal (MCP) joint flexion, and pinch (clamp) strength. Most of these measurements showed statistically significant improvements from baseline over 6 months. Five adverse events (injection site reactions) were reported in four patients (11.4%), and there were no serious or allergic reactions.Conclusion: This study suggests that viscosupplementation using NASHA is effective and well tolerated in treating the symptoms of rhizarthrosis. Keywords: Durolane, hyaluronic acid, osteoarthritis, pain, rhizarthrosis, viscosupplementation
format	article
author	Velasco E Ribera MV Pi J
author_facet	Velasco E Ribera MV Pi J
author_sort	Velasco E
title	Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
title_short	Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
title_full	Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
title_fullStr	Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
title_full_unstemmed	Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
title_sort	single-arm open-label study of durolane (nasha nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/1940463a5efd46819f8a718898548f4a
work_keys_str_mv	AT velascoe singlearmopenlabelstudyofdurolanenashanonanimalhyaluronicacidforthetreatmentofosteoarthritisofthethumb AT riberamv singlearmopenlabelstudyofdurolanenashanonanimalhyaluronicacidforthetreatmentofosteoarthritisofthethumb AT pij singlearmopenlabelstudyofdurolanenashanonanimalhyaluronicacidforthetreatmentofosteoarthritisofthethumb
_version_	1718400037901303808

Single-arm open-label study of Durolane (NASHA nonanimal hyaluronic acid) for the treatment of osteoarthritis of the thumb

Ejemplares similares